Sitland-Marken P A, Wells B G, Froemming J H, Chu C C, Brown C S
Division of Pharmacy Practice, School of Pharmacy, University of Missouri, Kansas City 64108-2792.
J Clin Psychiatry. 1990 Feb;51(2):68-82.
Bromocriptine, an ergot alkaloid derivative that possesses both dopamine agonist and antagonist activity, has been studied in a broad spectrum of psychiatric illnesses. The literature consists primarily of case reports and small trials limited by methodological shortcomings. The authors critically review these reports, focusing on efficacy, mechanistic issues, dosing, side effects, predictors of response, monitoring parameters, and practical guidelines. Preliminary data suggest bromocriptine may have promise in the treatment of neuroleptic malignant syndrome, cocaine withdrawal, and depression. At present, the agent appears less efficacious in the treatment of tardive dyskinesia, mania, and schizophrenia; however, doses in these trials may have been excessive, producing primarily postsynaptic agonist effects. More extensive clinical trials are required to clearly define the role of bromocriptine in psychiatry.
溴隐亭是一种麦角生物碱衍生物，兼具多巴胺激动剂和拮抗剂活性，已在多种精神疾病中进行了研究。相关文献主要是病例报告和受方法学缺陷限制的小型试验。作者对这些报告进行了批判性回顾，重点关注疗效、作用机制问题、给药剂量、副作用、反应预测因素、监测参数和实用指南。初步数据表明，溴隐亭在治疗抗精神病药恶性综合征、可卡因戒断和抑郁症方面可能有前景。目前，该药物在治疗迟发性运动障碍、躁狂症和精神分裂症方面似乎效果较差；然而，这些试验中的剂量可能过高，主要产生突触后激动剂效应。需要更广泛的临床试验来明确溴隐亭在精神病学中的作用。
